Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2016 1
2019 1
2020 1
2021 1
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.
Chuntova P, Hou Y, Naka R, Yamamichi A, Chen T, Goretsky Y, Hatae R, Nejo T, Kohanbash G, Mende AL, Montoya M, Downey KM, Diebold D, Skinner J, Liang HE, Schwer B, Okada H. Chuntova P, et al. Among authors: naka r. Neuro Oncol. 2022 Feb 1;24(2):259-272. doi: 10.1093/neuonc/noab182. Neuro Oncol. 2022. PMID: 34347086 Free PMC article.
Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone).
Naka R, Tada K, Kaneko H, Nagata O, Tashima M, Mizutani C, Imada K. Naka R, et al. Leuk Lymphoma. 2022 Jun;63(6):1508-1511. doi: 10.1080/10428194.2022.2032040. Epub 2022 Feb 2. Leuk Lymphoma. 2022. PMID: 35105261 No abstract available.
12 results